Estimation of Percentage of Patients With Fibroblast Growth Factor Receptor Alterations Eligible for Off-label Use of Erdafitinib

IMPORTANCE: When a novel drug is granted accelerated approval, both its on-label and off-label uses must be taken into account. OBJECTIVES: To estimate the potential upper bound of off-label use of erdafitinib to treat advanced cancer with fibroblast growth factor receptor gene (FGFR) alterations, c...

Descripción completa

Detalles Bibliográficos
Autores principales: de Almeida Carvalho, Lelia Maria, de Oliveira Sapori Avelar, Sandra, Haslam, Alyson, Gill, Jennifer, Prasad, Vinay
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2019
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6902826/
https://www.ncbi.nlm.nih.gov/pubmed/31755953
http://dx.doi.org/10.1001/jamanetworkopen.2019.16091

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6902826/
https://www.ncbi.nlm.nih.gov/pubmed/31755953
http://dx.doi.org/10.1001/jamanetworkopen.2019.16091

Ejemplares similares